Eswatini vs Mus: Estimated antiretroviral therapy coverage among people living with HIV
Eswatini
95.0%
in 2025
Mus
36.0%
in 2025
Eswatini rank
5th
Mus rank
2nd
Estimated antiretroviral therapy coverage among people living with HIV over time
- Eswatini
- Mus
How they compare
Eswatini currently reports 95.0% against 36.0% in Mus, a difference of 59.0%.
That makes Eswatini's figure about 2.6 times Mus's.
The two have swapped places 1 time across 26 shared years of data; in 2000 it was Mus ahead.
Eswatini ranks 5th and Mus ranks 2nd of 143 countries.
Eswatini has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Eswatini | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 7.6% | 2.9% | 4.7% | Eswatini |
| 2010s | 57.5% | 20.5% | 37.0% | Eswatini |
| 2020s | 91.8% | 30.7% | 61.2% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher estimated antiretroviral therapy coverage among people living with hiv, Eswatini or Mus?
- Eswatini, at 95.0% against 36.0% in Mus as of 2025.
- What is the difference in estimated antiretroviral therapy coverage among people living with hiv between Eswatini and Mus?
- 59.0%, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Mus?
- 26 years are reported by both, from 2000 to 2025.
- How do Eswatini and Mus rank globally for estimated antiretroviral therapy coverage among people living with hiv?
- Eswatini ranks 5th and Mus ranks 2nd of 143 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Estimated antiretroviral therapy coverage among people living with HIV (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.